Xianwei Biological: The world’s first GLP-1 weight-loss drug with receptor selectivity approved for market launch

2026-04-11 04:57:18

On March 6th, Daxing Biotech announced: the world’s first cAMP-biased GLP-1 receptor agonist, Enopeglutide Injection (Xianweiying), has been approved for market by the National Medical Products Administration (NMPA), suitable for long-term weight management in adult overweight/obese patients based on controlled diet and increased physical activity. (People’s Financial News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes